ClearPoint Neuro (CLPT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.38
- Estimate
- -$0.29
- Surprise
- -32.6%
- Revenue (period 2026-06-30)
- $10.9M
- Score at report (before → after)
- 5.2 → 5.4/10
Revenue source: xbrl.
How the report landed
ClearPoint Neuro (CLPT) reported a wider loss than forecast — adjusted EPS of -$0.38 against the -$0.29 estimate (a 32.6% shortfall). TrendMatrix's engine moved from Sell (5.2/10) to Hold at 5.4/10 after the report — the engine's score rose despite the miss.
Where TrendMatrix's rating stands now
TrendMatrix currently rates CLPT Hold at 4.7/10.
0 of the last 4 quarters beat the estimate; this quarter's -32.6% surprise compares with a -22.4% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Market cap $336M below $400M minimum
- Momentum score 2.1/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $11.01
- Price target
- $19.97
- Stop
- $10.29
- Upside to target
- +81.4%
- Reward-to-risk
- 5.4:1
Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.
CLPT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $335.9M
- P/E (fwd)
- -9.2
- 52-week range
- $8.27–$30.10
- Off 52-week high
- 63.4%
- RSI (14)
- 39
- Volume vs avg
- 1.20×
- Score today
- 4.7/10